Standard BioTools delivered Q4 revenue of $23.8 million, down 4% year-over-year, but showed improved operational efficiency. The company successfully operationalized over $40 million in annualized cost savings and significantly improved its net income position due to a one-time tax benefit, while maintaining a strong cash position of approximately $550 million following the SomaLogic transaction.

For Q2 2025, continuing operations delivered $21.762M in revenue, a GAAP operating loss of $25.697M, and a net loss of $17.673M; GAAP gross margin improved to 48.8% and non‑GAAP gross margin reached 54.1%.

Standard BioTools delivered a solid first quarter in line with expectations, with revenue of $40.8 million, a 10% decrease year-over-year. Despite the revenue decline, the company significantly reduced its operating loss by 45% and improved adjusted EBITDA by 29% year-over-year, reflecting focused execution and cost reductions.

Standard BioTools announced its financial results for the fourth quarter and full fiscal year ended December 31, 2024. The company reported a total revenue of $46.7 million for Q4 2024, with a net loss of $34.1 million and an adjusted EBITDA loss of $18.4 million, showing improvements compared to the previous year.

Standard BioTools reported Q3 2024 revenue of $45 million. The company focused on driving commercial execution and enhancing overall operating efficiency, which led to a 50% adjusted EBITDA improvement and a 35% net loss improvement year-over-year.

Standard BioTools reported revenue of $37.2 million for Q2 2024. The company is focused on optimizing cost structure and accelerating merger synergies, expecting to operationalize $80 million in cost reductions by the end of 2024. They are on track to achieve adjusted EBITDA break-even for the full year 2026 and have a current balance sheet of $396 million in cash, cash equivalents, restricted cash, and short-term investments.

Standard BioTools reported a 4% increase in revenue for the fourth quarter of 2023. The company also achieved substantial reductions in expenses and cash burn while expanding gross margins. The merger with SomaLogic was completed, with combined pro forma revenue for FY2023 totaling $192 million.

Standard BioTools reported its Q3 2023 financial results, showing revenue of $25.4 million. The company is maintaining a disciplined approach to commercial and R&D investment. They have raised their 2023 financial outlook, and believe they are well on track to execute their long-term transformation plan.

Standard BioTools reported a 5.2% decrease in GAAP revenue year-over-year to $25.1 million, while core product and service revenue increased 1.8% to $24.3 million. The company significantly reduced operating cash burn and saw improvements in GAAP and non-GAAP product and service margins. They also completed restructuring efforts and are focused on inorganic growth.

Standard BioTools reported Q4 2022 GAAP revenues of $27.0 million. Core product and service revenues were $26.8 million, representing 8.3% sequential growth. The company's restructuring initiatives contributed to a 16% sequential decrease in operating expenses and improved product and services margin.

Standard BioTools announced its third quarter 2022 financial results, highlighting a sequential increase in core product and services revenue and improvements in operating margin due to restructuring efforts. The company is focused on commercial execution, operational efficiency, and expense reduction.

Standard BioTools reported a decrease in revenue to $18.8 million compared to $31.0 million in the second quarter of 2021. The company has initiated a restructuring plan to return to growth, improve gross margins, and reduce operating cash burn. They also completed a $250 million strategic cash infusion.

Standard BioTools announced first quarter 2022 financial results with a total revenue of $26.5 million, compared to $32.8 million in Q1 2021. The company reported a GAAP net loss of $76.3 million and a non-GAAP net loss of $19.5 million. They completed a $250 million capital infusion.

Fluidigm Corporation reported a total revenue of $38.3 million for Q4 2021, compared to $44.6 million for Q4 2020. Base product and service revenue (excluding COVID-19 testing revenue) increased 13.5 percent to $35.3 million. The GAAP net loss for the quarter was $9.4 million, compared to a GAAP net loss of $18.0 million for the same period last year.

Fluidigm Corporation reported a decrease in total revenue for Q3 2021 compared to Q3 2020, primarily due to supply chain constraints and regional impacts in APAC. The company's board is undertaking a review of options to maximize stockholder value. Base product and service revenue saw a slight increase, but the company faced challenges in fulfilling orders, resulting in a significant backlog.

Fluidigm Corporation announced financial results for the second quarter ended June 30, 2021, with total revenue of $31.0 million, a 19% increase from Q2 2020. The company's base product and service revenue (excluding COVID-19 testing revenue) increased by 33% year-over-year. However, the GAAP net loss was $17.1 million, compared to a net loss of $13.0 million for the second quarter of 2020.

Fluidigm Corporation announced financial results for the first quarter ended March 31, 2021, with total revenue of $32.8 million, a 19 percent increase over the prior year period. The company's GAAP net loss was $18.8 million, and non-GAAP net loss was $11.1 million. They are revising 2021 revenue and net loss guidance due to the decline in COVID-19 testing revenue.

Fluidigm Corporation reported a 38% increase in fourth-quarter revenue to $44.6 million, driven by microfluidics and mass cytometry performance. The company delivered record-breaking full-year revenue and made progress in molecular diagnostics and immune research strategies.

Fluidigm Corporation announced strong third-quarter results, driven by COVID-19 testing and clinical research strategies. Total revenue increased by 50 percent to $39.9 million, with product and service revenue up 34 percent to $35.3 million. The company reported a GAAP net loss of $6.0 million and a non-GAAP net income of $2.5 million.

Fluidigm Corporation announced financial results for the second quarter ended June 30, 2020. The company has pivoted to meet testing and immune profiling research needs brought on by the pandemic. They filed for Emergency Use Authorization for their extraction-free saliva test and were selected for a project to expand COVID-19 testing under the National Institutes of Health Rapid Acceleration of Diagnostics initiative.

Fluidigm Corporation reported a decrease in revenue for the first quarter of 2020, but is focusing on new opportunities related to COVID-19, including testing infrastructure and immune response measurement.

Fluidigm Corporation reported strong sequential quarterly growth in Q4 2019, driven by customer adoption of Imaging Mass Cytometry™ and launched over 10 new products for the mass cytometry business.